Novo Nordisk Earnings: Wegovy Supply & Obesity Pipeline in Focus

Second quarter results came in below expectations, but we maintain our fair value estimates for Novo Nordisk 

Karen Andersen, CFA 8 August, 2024 | 8:33AM
Facebook Twitter LinkedIn

novo flags

We’re maintaining our DKK600/USD86 fair value estimates for wide-moat pharmaceutical giant Novo Nordisk (NOVO B) following second-quarter results that were slightly below our very high expectations, but not enough to significantly sway our full-year expectations.

Key Morningstar Metrics for Novo Nordisk

• Fair Value Estimate: DKK600
• Morningstar Rating: ★★
• Economic Moat: Wide
• Morningstar Uncertainty Rating: High

What We Thought of Novo Nordisk's Earnings

Novo Nordisk's revenue grew 25% at constant currencies, with 32% GLP-1 diabetes growth (largely Ozempic) and 37% GLP-1 obesity growth (Wegovy). Management slightly raised its expected 2024 sales growth by 2 percentage points at the midpoint to 22%-28% at constant exchange rates (from a prior range of 19%-27%).

Excluding an impairment related to a failed trial of cardiovascular drug ocedurenone, management’s 2024 operating profit growth expectations increased by roughly 4 percentage points, and we think the firm looks on track to produce solid double-digit performance in line with the midpoint of guidance in the second half. 

Novo Nordisk Shares Look Overvalued

We still think Novo’s GLP-1 business across therapeutic areas will peak above 70 billion USD in 2031, although we remain less confident in its ability to grow beyond the 2032 patent expiration for semaglutide, the molecule in Ozempic and Wegovy.

While we continue to see Novo Nordisk as a wide-moat firm, with strong intangible assets surrounding its cardiometabolic business, we think high obesity drug demand and supply constraints have pushed shares above their intrinsic value. In our obesity forecast, we’re weighing the upside from potentially positive data later this year for monlunabant and CagriSema against downside from poor compliance rates and increased competition on the horizon.

Novo's Drug Pipeline Under Pressure

We expect price declines to accelerate in the obesity market as access expands to more patients with private insurance and Medicaid. Recent data from several challengers looks competitive with data for Wegovy and Eli Lilly’s Zepbound, and we think launches in 2027-29 could begin to erode share and put further pressure on price.

We’re most concerned about Novo’s reliance on peptide manufacturing, which requires significant fill-finish capacity and larger volumes if it intends to launch an oral version of semaglutide (it is still unclear whether it will launch this product in obesity, despite positive phase 3 readouts). Competitors such as Lilly, Roche, Structure, and AstraZeneca have oral small molecule programs that would be much easier to manufacture at large scale.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
AstraZeneca PLC1,661.50 SEK-1.45
AstraZeneca PLC ADR80.62 USD1.73Rating
Eli Lilly and Co772.14 USD-2.65Rating
Novo Nordisk A/S Class B837.90 DKK1.15Rating
Roche Holding AG271.50 CHF-0.98Rating
Structure Therapeutics Inc ADR34.03 USD-3.10

About Author

Karen Andersen, CFA  Karen Andersen, CFA, is a senior stock analyst with Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures